jpg.jpg
Incysus Therapeutics to Present at the 2019 Society for Neuro-Oncology (SNO) Annual Meeting
November 21, 2019 07:00 ET | Incysus Therapeutics, Inc.
NEW YORK, Nov. 21, 2019 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the...
download.jpg
Gamma-Delta (γδ) T Cell Therapy Combined With Checkpoint Inhibition Shows Potential Synergies in Vitro for Treatment of Glioblastoma
November 15, 2018 07:00 ET | Incysus Therapeutics, Inc.
Promising data from gamma-delta (γδ) T cell therapy in combination with checkpoint inhibitors to be presented at 2018 Society for Neuro-Oncology annual meeting NEW YORK, Nov. 15, 2018 (GLOBE...
VBI-Vaccines-Vertical-Logo.png
VBI Vaccines to Present Initial Data for VBI-1901 in Recurrent Glioblastoma (GBM) Patients at the 2018 Annual Meeting of the Society for Neuro-Oncology (SNO)
October 24, 2018 08:00 ET | VBI Vaccines, Inc.
CAMBRIDGE, Mass., Oct. 24, 2018 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and...